Tag Archives: NIH

News, Politics, Government

Chelation Trial Investigators Respond to Questions

Leave a comment

By Harlan Krumholz, Contributor

JAMA’s publication the NIH’s Trial to Assess Chelation Therapy (TACT) unleashed a spate of criticism directed at the investigators and their science. The trial showed that patients randomized to chelation therapy had a lower risk of a combined endpoint of death, heart attack, stroke, percutaneous coronary intervention, bypass surgery or hospitalization for angina than those who received a placebo infusion. I wrote in a Forbes blog that I found the results to be surprising and inconvenient – I did not think that the evidence was strong enough to make me recommend the therapy to others – I said that there is a need to replicate such surprising findings – but I noted that the results should not merely be dismissed – they deserved attention and merited discussion. …read more

Source: FULL ARTICLE at Forbes Latest

White House Press Office

Remarks by the President on the BRAIN Initiative and American Innovation

Leave a comment

By The White House

East Room
10:04 A.M. EDT
THE PRESIDENT: Thank you so much. (Applause.) Thank you, everybody. Please have a seat. Well, first of all, let me thank Dr. Collins not just for the introduction but for his incredible leadership at NIH. Those of you who know Francis also know that he’s quite a gifted singer and musician. So I was asking whether he was going to be willing to sing the introduction — (laughter) — and he declined.
But his leadership has been extraordinary. And I’m glad I’ve been promoted Scientist-in-Chief. (Laughter.) Given my grades in physics, I’m not sure it’s deserving. But I hold science in proper esteem, so maybe that gives me a little credit.
Today I’ve invited some of the smartest people in the country, some of the most imaginative and effective researchers in the country — some very smart people to talk about the challenge that I issued in my State of the Union address: to grow our economy, to create new jobs, to reignite a rising, thriving middle class by investing in one of our core strengths, and that’s American innovation.
Ideas are what power our economy. It’s what sets us apart. It’s what America has been all about. We have been a nation of dreamers and risk-takers; people who see what nobody else sees sooner than anybody else sees it. We do innovation better than anybody else — and that makes our economy stronger. When we invest in the best ideas before anybody else does, our businesses and our workers can make the best products and deliver the best services before anybody else.
And because of that incredible dynamism, we don’t just attract the best scientists or the best entrepreneurs — we also continually invest in their success. We support labs and universities to help them learn and explore. And we fund grants to help them turn a dream into a reality. And we have a patent system to protect their inventions. And we offer loans to help them turn those inventions into successful businesses.
And the investments don’t always pay off. But when they do, they change our lives in ways that we could never have imagined. Computer chips and GPS technology, the Internet — all these things grew out of government investments in basic research. And sometimes, in fact, some of the best products and services spin off completely from unintended research that nobody expected to have certain applications. Businesses then used that technology to create countless new jobs.
So the founders of Google got their early support from the National Science Foundation. The Apollo project that put a man on the moon also gave us eventually CAT scans. And every dollar we spent to map the human genome has returned $140 to our economy — $1 of investment, …read more
Source: White House Press Office
White House Press Office

Fact Sheet: BRAIN Initiative

Leave a comment

By The White House

“If we want to make the best products, we also have to invest in the best ideas… Every dollar we invested to map the human genome returned $140 to our economy… Today, our scientists are mapping the human brain to unlock the answers to Alzheimer’s… Now is not the time to gut these job-creating investments in science and innovation. Now is the time to reach a level of research and development not seen since the height of the Space Race.”

– President Barack Obama, 2013 State of the Union

In his State of the Union address, the President laid out his vision for creating jobs and building a growing, thriving middle class by making a historic investment in research and development.

Today, at a White House event, the President unveiled a bold new research initiative designed to revolutionize our understanding of the human brain. Launched with approximately $100 million in the President’s Fiscal Year 2014 Budget, the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative ultimately aims to help researchers find new ways to treat, cure, and even prevent brain disorders, such as Alzheimer’s disease, epilepsy, and traumatic brain injury.

The BRAIN Initiative will accelerate the development and application of new technologies that will enable researchers to produce dynamic pictures of the brain that show how individual brain cells and complex neural circuits interact at the speed of thought. These technologies will open new doors to explore how the brain records, processes, uses, stores, and retrieves vast quantities of information, and shed light on the complex links between brain function and behavior.

This initiative is one of the Administration’s “Grand Challenges” – ambitious but achievable goals that require advances in science and technology. In his remarks today, the President called on companies, research universities, foundations, and philanthropists to join with him in identifying and pursuing the Grand Challenges of the 21st century.

The BRAIN Initiative includes:

  • Key investments to jumpstart the effort: The National Institutes of Health, the Defense Advanced Research Projects Agency, and the National Science Foundation will support approximately $100 million in research beginning in FY 2014.

  • Strong academic leadership: The National Institutes of Health will establish a high-level working group co-chaired by Dr. Cornelia “Cori” Bargmann (The Rockefeller University) and Dr. William Newsome (Stanford University) to define detailed scientific goals for the NIH’s investment, and to develop a multi-year scientific plan for achieving these goals, including timetables, milestones, and cost estimates.

  • Public-private partnerships: Federal research agencies will partner with companies, foundations, and private research institutions that are also investing in relevant neuroscience research, such as the Allen Institute, the Howard Hughes Medical Institute, the Kavli Foundation, and the Salk Institute for Biological Studies.

  • Maintaining our highest ethical standards: Pioneering research often has the potential to raise new ethical challenges. To ensure this new effort proceeds in ways that continue to adhere to our highest standards of research protections, the President will direct his Commission for the Study of Bioethical Issues to explore the ethical, legal, and societal implications raised by this research …read more
    Source: White House Press Office

Science & Technology

Controversial NIH Chelation Trial Published In JAMA

Leave a comment

By Larry Husten Final results of the troubled NIH-sponsored TACT trial testing chelation therapy for coronary disease have now been published in JAMA. Last November, when the preliminary results were presented at the American Heart Association meeting, the positive finding in favor of chelation therapy surprised many observers, though the investigators and senior AHA representatives expressed considerable caution about the proper interpretation of the results. Full publication of the main results should now allow for a more thorough consideration of the trial. …read more
Source: FULL ARTICLE at Forbes Technology

Health

Sen. Wyden's Proposal Will Kill NIH-Pharma Collaboration

Leave a comment

By John LaMattina In the 1980s, Congress was growing increasingly concerned about the competitiveness of U.S. industry, particularly with respect to the timely transfer of technology from government labs to the private sector. Thus, in 1986, it passed the Federal Technology Transfer Act (FTTA). The FTTA allowed government laboratories like the National Institutes of Health (NIH) to enter into Cooperative Research and Development Agreements (CRADAs) with the pharmaceutical industry. With a CRADA in place, scientists at the NIH were allowed to conduct collaborative research with industry scientists to promote the discovery of new drugs. …read more
Source: FULL ARTICLE at Forbes Health

Business, Finance, Occupation & Industry

Data on Provectus's PV-10 to Be Presented at the HemOnc Today – Melanoma and Cutaneous Malignancies

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Data on Provectus’s PV-10 to Be Presented at the HemOnc Today – Melanoma and Cutaneous Malignancies Conference on March 22, 2013

KNOXVILLE, Tenn.–(BUSINESS WIRE)– Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that data on PV-10 for metastatic melanoma will be included in a presentation at the HemOnc Today – Melanoma and Cutaneous Malignancies Conference on Friday, March 22, 2013 in New York.

Dr. Robert H.I. Andtbacka, Assistant Professor of Surgical Oncology, Huntsman Cancer Institute at the University of Utah in Salt Lake City, is scheduled to present during conference session on Local-Regional Therapy. His presentation, “Current Status of Injectable Therapy” begins at 1:55 p.m., EDT. This session will be moderated by Sanjiv S. Agarwala, MD, Principal Investigator for the Phase 2 trial of PV-10, and Chief of Medical Oncology and Hematology at St. Luke’s Hospital and Health Network in Bethlehem, PA.

Dr. Craig Dees, PhD, CEO of Provectus said, “We are pleased to be participating in this important conference. We expect Dr. Andtbacka’s presentation will support PV-10’s utility in the treatment of metastatic melanoma.”

About Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company’s other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company’s website at www.pvct.com or contact Porter, LeVay & Rose, Inc.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to …read more
Source: FULL ARTICLE at DailyFinance

News, Politics, Government

A Genomics Argument About Why The NIH Is Good For Business

Leave a comment

By Matthew Herper, Forbes Staff I wanted to find this yesterday, but didn’t get to it until today: A quote from Elaine Mardis, the Washington University in St.Louis DNA sequencing expert, about how cuts to NIH funding are hurting genomics companies like Illumina, Life Technologies, and Pacific Biosciences, even though they represent one of the few U.S. industry’s making something of value.  Strong words: …read more
Source: FULL ARTICLE at Forbes Latest

Linux

Fetch entries with specific pattern

Leave a comment

By kareena

Hi all,

I have following sample input file which is a part of big file:

Code:
ID AINX_HUMAN Reviewed; 499 AA.
AC Q16352; B1AQK0; Q9BRC5;
DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT 23-JAN-2002, sequence version 2.
DT 28-NOV-2012, entry version 123.
DE RecName: Full=Alpha-internexin;
DE Short=Alpha-Inx;
DE AltName: Full=66 kDa neurofilament protein;
DE Short=NF-66;
DE Short=Neurofilament-66;
DE AltName: Full=Neurofilament 5;
GN Name=INA; Synonyms=NEF5;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT SER-92.
RC TISSUE=Fetal brain;
RX MEDLINE=95287809; PubMed=7769995;
RA Chan S.-O., Chiu F.-C.;
RT "Cloning and developmental expression of human 66 kd neurofilament
RT protein.";
RL Brain Res. Mol. Brain Res. 29:177-184(1995).
RN [2]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX PubMed=15164054; DOI=10.1038/nature02462;
RA Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT "The DNA sequence and comparative analysis of human chromosome 10.";
RL Nature 429:375-381(2004).
RN [3]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA Venter J.C.;
RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN [4]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC TISSUE=Brain;
RX PubMed=15489334;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA
RT project: the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [5]
RP PROTEIN SEQUENCE OF 46-83; 105-111; 121-130; 139-145; 216-228;
RP 279-288; 323-330; 339-367; 378-397 AND 407-430, AND MASS SPECTROMETRY.
RC TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA Lubec G., Afjehi-Sadat L., Chen W.-Q., Sun Y.;
RL Submitted (DEC-2008) to UniProtKB.
RN [6]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-496, AND MASS
RP SPECTROMETRY.
RC TISSUE=Embryonic kidney;
RX PubMed=17525332;
RA Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT "ATM and ATR substrate analysis reveals extensive protein networks
RT responsive to DNA damage.";
RL Science 316:1160-1166(2007).
RN [7]
RP ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-290, AND MASS SPECTROMETRY.
RX PubMed=19608861; DOI=10.1126/science.1175371;
RA Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,
RA Olsen J.V., Mann M.;
RT "Lysine acetylation targets protein complexes and co-regulates major
RT cellular functions.";
RL Science 325:834-840(2009).
RN [8]
RP VARIANT [LARGE SCALE ANALYSIS] GLN-110.
RX PubMed=16959974; DOI=10.1126/science.1133427;
RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT "The consensus coding sequences of human breast and colorectal
RT cancers.";
RL Science 314:268-274(2006).
CC -!- FUNCTION: Class-IV neuronal intermediate filament that is able to
CC self-assemble. It is involved in the morphogenesis of neurons. It
CC may form an independent structural network without the involvement
CC of other neurofilaments or it may cooperate with NF-L to form the
CC filamentous backbone to which NF-M and NF-H attach to form the
CC cross-bridges.
CC -!- TISSUE SPECIFICITY: Found predominantly in adult CNS.
CC -!- DEVELOPMENTAL STAGE: Expressed in brain as early as the 16th week
CC of gestation, and increased rapidly and reached a steady state
CC level by the 18th week of gestation.
CC -!- PTM: O-glycosylated (By similarity).
CC -!- PTM: Phosphorylated upon DNA damage, probably by ATM or ATR.
CC -!- SIMILARITY: Belongs to the intermediate filament family.
CC -----------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----------------------------------------------------------------------
DR EMBL; S78296; AAB34482.1; -; mRNA.
DR EMBL; AL591408; CAI16744.1; -; Genomic_DNA.
DR EMBL; CH471066; EAW49653.1; -; Genomic_DNA.
DR EMBL; BC006359; AAH06359.1; -; mRNA.
DR IPI; IPI00001453; -.
DR PIR; I52658; I52658.
DR RefSeq; NP_116116.1; NM_032727.3.
DR UniGene; Hs.500916; -.
DR ProteinModelPortal; Q16352; -.
DR SMR; Q16352; 90-241, 259-329, 333-402.
DR IntAct; Q16352; 3.
DR STRING; Q16352; -.
DR PhosphoSite; Q16352; -.
DR DMDM; 20141266; -.
DR PaxDb; Q16352; -.
DR PeptideAtlas; Q16352; -.
DR PRIDE; Q16352; -.
DR DNASU; 9118; -.
DR Ensembl; ENST00000369849; ENSP00000358865; ENSG00000148798.
DR GeneID; 9118; -.
DR KEGG; hsa:9118; -.
DR UCSC; uc001kws.3; human.
DR CTD; 9118; -.
DR GeneCards; GC10P105026; -.
DR HGNC; HGNC:6057; INA.
DR HPA; CAB002059; -.
DR HPA; HPA008057; -.
DR MIM; 605338; gene.
DR neXtProt; NX_Q16352; -.
DR PharmGKB; PA29867; -.
DR eggNOG; NOG149366; -.
DR HOGENOM; HOG000230977; -.
DR HOVERGEN; HBG013015; -.
DR InParanoid; Q16352; -.
DR KO; K07608; -.
DR OMA; ASSYRKV; -.
DR OrthoDB; EOG4R5031; -.
DR PhylomeDB; Q16352; -.
DR GenomeRNAi; 9118; -.
DR NextBio; 34171; -.
DR ArrayExpress; Q16352; -.
DR Bgee; Q16352; -.
DR CleanEx; HS_INA; -.
DR Genevestigator; Q16352; -.
DR GermOnline; ENSG00000148798; Homo sapiens.
DR GO; GO:0005883; C:neurofilament; TAS:ProtInc.
DR GO; GO:0005200; F:structural constituent of cytoskeleton; TAS:ProtInc.
DR GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR GO; GO:0007399; P:nervous system development; IEA:UniProtKB-KW.
DR GO; GO:0060052; P:neurofilament cytoskeleton organization; IEA:Compara.
DR GO; GO:0042246; P:tissue regeneration; IEA:Compara.
DR InterPro; IPR016044; F.
DR InterPro; IPR001664; IF.
DR InterPro; IPR006821; Intermed_filament_DNA-bd.
DR InterPro; IPR018039; Intermediate_filament_CS.
DR PANTHER; PTHR23239; PTHR23239; 1.
DR Pfam; PF00038; Filament; 1.
DR Pfam; PF04732; Filament_head; 1.
DR PROSITE; PS00226; IF; 1.
PE 1: Evidence at protein level;
KW Acetylation; Coiled coil; Complete proteome; Developmental protein;
KW Differentiation; Direct protein sequencing; Glycoprotein;
KW Intermediate filament; Neurogenesis; Phosphoprotein; Polymorphism;
KW Reference proteome.
FT CHAIN 1 499 Alpha-internexin.
FT /FTId=PRO_0000063783.
FT REGION 1 87 Head.
FT REGION 88 408 Rod.
FT REGION 88 129 Coil 1A.
FT REGION 130 142 Linker 1.
FT REGION 143 238 Coil 1B.
FT REGION 239 262 Linker 2.
FT REGION 263 408 Coil 2.
FT REGION 409 499 Tail.
FT COMPBIAS 449 454 Poly-Glu.
FT MOD_RES 72 72 Phosphoserine (By similarity).
FT MOD_RES 290 290 N6-acetyllysine.
FT MOD_RES 335 335 Phosphoserine (By similarity).
FT MOD_RES 496 496 Phosphoserine.
FT VARIANT 92 92 T -> S (in dbSNP:rs1063455).
FT /FTId=VAR_049808.
FT VARIANT 110 110 E -> Q (in a breast cancer sample;
FT somatic mutation).
FT /FTId=VAR_036369.
FT VARIANT 149 149 D -> H (in dbSNP:rs1063456).
FT /FTId=VAR_033497.
FT CONFLICT 37 41 GFRSQ -> ASVE (in Ref. 1; AAB34482).
FT CONFLICT 67 67 R -> A (in Ref. 1; AAB34482).
FT CONFLICT 128 132 ALRQR -> RCDT (in Ref. 1; AAB34482).
FT CONFLICT 141 141 E -> Q (in Ref. 1; AAB34482).
FT CONFLICT 147 152 LRDLRA -> PRHLP (in Ref. 1; AAB34482).
FT CONFLICT 191 198 GAERALKA -> RRARLKR (in Ref. 1;
FT AAB34482).
FT CONFLICT 244 244 A -> R (in Ref. 1; AAB34482).
FT CONFLICT 263 263 S -> A (in Ref. 1; AAB34482).
FT CONFLICT 301 301 S -> T (in Ref. 1; AAB34482).
FT CONFLICT 310 311 EE -> DQ (in Ref. 1; AAB34482).
FT CONFLICT 318 318 Missing (in Ref. 1; AAB34482).
SQ SEQUENCE 499 AA; 55391 MW; 4C972764E9E68D3E CRC64;
MSFGSEHYLC SSSSYRKVFG DGSRLSARLS GAGGAGGFRS QSLSRSNVAS SAACSSASSL
GLGLAYRRPP ASDGLDLSQA AARTNEYKII RTNEKEQLQG LNDRFAVFIE KVHQLETQNR
ALEAELAALR QRHAEPSRVG ELFQRELRDL RAQLEEASSA RSQALLERDG LAEEVQRLRA
RCEEESRGRE GAERALKAQQ RDVDGATLAR LDLEKKVESL LDELAFVRQV HDEEVAELLA
TLQASSQAAA EVDVTVAKPD LTSALREIRA QYESLAAKNL QSAEEWYKSK FANLNEQAAR
STEAIRASRE EIHEYRRQLQ ARTIEIEGLR GANESLERQI LELEERHSAE VAGYQDSIGQ
LENDLRNTKS EMARHLREYQ DLLNVKMALD IEIAAYRKLL EGEETRFSTS GLSISGLNPL
PNPSYLLPPR ILSATTSKVS STGLSLKKEE EEEEASKVAS KKTSQIGESF EEILEETVIS
TKKTEKSNIE ETTISSQKI

the expected output is to fetch entries: AC entries and CC entries infront of which -!- is present with FUNCTION. It should print only the sentences in FUNCTION before the next -!- entries come.

Code:
AC Q16352; B1AQK0; Q9BRC5;
CC -!- FUNCTION: Class-IV neuronal intermediate filament that is able to self-assemble. It is involved in the morphogenesis of neurons. It may form an independent structural network without the involvement of other euro filaments or it may cooperate with NF-L to form the filamentous backbone to which NF-M and NF-H attach to form the cross-bridges.

Please let me know relevant shell scripting. I tried awk and sed it doesnt work.

Source: FULL ARTICLE at The UNIX and Linux Forums